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This study documents the analysis of a hitherto unreported dynamic behavior of androgen receptor (AR), a member of the nuclear receptor
superfamily. Employing GFP-tagged AR, we observed agonist-mediated docking of AR onto the mitotic chromatin during all the stages of
mitosis. When bound to therapeutic drugs with intrinsically absolute or partial agonistic properties, AR concomitantly associated with the mitotic
chromatin. Conversely, pure antagonists known to bind and subsequently translocate unliganded AR from cytoplasm to nuclear compartment did
not provoke such association. The agonist-mediated docking of AR could not be competed with other transcription factors that constitutively
preoccupied the chromosomal docking sites. Amongst the previously reported proteins, AR is first example of a transcription factor whose
response on mitotic chromatin platform can be modulated in a ligand-specific manner. However, data from live cell imaging revealed that co-
activators of agonist-activated receptor that are recruited into “nuclear foci” of interphase chromatin are dislodged from the mitotic chromatin
during cell division. This implies that in absence of critical co-activators, AR transverses mitotic phase in transcriptionally silenced state. Finally,
our results indicate that ligand-mediated dynamic relationship of nuclear receptors with mitotic chromatin can be effectively exploited to study,
analyze and authenticate therapeutic ligands.
© 2007 Elsevier B.V. All rights reserved.Keywords: Steroid receptor; Mitotic chromatin; Antiandrogen; Prostate cancer1. Introduction
Androgen Receptor (AR) is a member of the nuclear receptor
(NR) superfamily that acts as a ligand-activated transcription
factor. AR plays a major role in the development and main-
tenance of male sex characteristics by executing the biological
functions of androgens. AR also has an important role in pro-
state cell proliferation and differentiation; and during androgen-
responsive prostate cancer, manipulation of AR function by
antiandrogenic drugs is the primary mode of treatment of the
malignancy [1–3]. As a member of steroid/nuclear receptor
superfamily, AR is structurally characterized by an amino-
terminal domain (N-terminal) containing activation function 1
(AF-1); a central DNA binding domain; and, a multifunctional
carboxyl-terminal domain (C-terminal) involved in receptor⁎ Corresponding author. Tel.: +91 11 2674 1544; fax: +91 11 26741781.
E-mail addresses: rktyagi@yahoo.com, rkt2300@mail.jnu.ac.in
(R.K. Tyagi).
0167-4889/$ - see front matter © 2007 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamcr.2007.11.002dimerization, ligand binding and activation function 2 (AF-2).
For transcription function of AR, interaction between N/C-
termini is modulated in ligand-dependent fashion. For example,
agonists induce the N/C interaction while antagonist (like
casodex, hydroxyflutamide etc.) do not induce detectable N/C
interaction [4–6]. Recently, N/C interaction are reported to play
an important role in the control of AR-chromatin binding and
also for the recruitment of SWI/SNF complex that in turn re-
models chromatin to allow AR to bind to AR response element
in interphase chromatin [5]. Also, AR N/C interactions take
place predominantly when AR is mobile, possibly to prevent
unfavorable or untimely cofactor interactions [7].
Unliganded AR is a cytoplasmic protein that upon androgen
binding translocates to the nucleus. In the nucleus it binds to the
regulatory regions of androgen-responsive genes and subse-
quently modulates their transcription [6,8,9]. Conversely, most
of the antiandrogenic compounds though bind and translo-
cate cytoplasmic AR to nuclear compartment but essentially in-
hibit or impede its transcriptional function. These antiandrogens
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flutamide, casodex (bicalutamide), nilutamide etc. that have
gained widespread use in treatment of androgen-dependent
prostate cancer [10,11]. Since these antiandrogens can efficiently
inhibit or diminish AR-mediated gene expression, they are
therefore useful tools in the treatment of androgen-dependent
prostate cancer. Antiandrogens are either complete or partial
inhibitors of AR activity, depending on the nature of the
therapeutic molecule. Recent studies demonstrate that AR
antagonists facilitate AR-DNA binding but inhibit transcrip-
tional activation by the recruitment of corepressors [12,13]. As
compared to androgens, antiandrogens induce a different AR
conformation, thereby influencing the recruitment of co-
regulators (co-activators and corepressors) [8,14]. In a classical
finding this ligand-selective modulation of AR activity was also
broadened by mutation in AR (T877A and T857A substitution)
found in prostate cancer [3,15].
Discovery of green fluorescent protein (GFP) and availability
of multi-colored fluorescent variants, in conjunction with the
advances in fluorescence microscopy, have helped in revealing
finer details of protein localization and subcellular dynamics in
living cells [16]. In principle, all intracellular steroid receptors
when bound to their cognate hormones are nuclear and tran-
scriptionally active. However, subcellular localization of unli-
ganded receptors varies from being predominantly cytoplasmic
[e.g. AR, glucocorticoid receptor (GR)] to predominantly
nuclear [e.g. estrogen receptor (ERα), progesterone receptor].
Also, data obtained from GFP-tagged steroid receptors ex-
pressed and imaged from live cells have consistently shown that
agonist-bound receptors in nucleus reorganize into speckled
pattern revealing discrete receptor accumulation into 250–400
fluorescent speckles [9,17,18]. These have been commonly
referred to as “nuclear foci”. The initial speculation that “nuclear
foci” represent transcriptionally active form of steroid receptors
while homogeneously distributed receptor represents transcrip-
tionally inactive receptor has drawn substantial experimental
support [18–20]. Subsequent studies in live cells have shown
that some of the co-activators or basal transcription factors like
GRIP1, TIF2, CBP, SRC-1, SRC-3 etc. co-localize with agonist-
activated AR in “nuclear foci” but not with pure antagonist-
bound steroid receptors [21–25]. Thus, agonist-generated “nu-
clear foci” were suggestive of multi-protein complexes required
for activation of hormone responsive genes [reviewed in
9,19,26]. Hager's laboratory [6,27] has provided direct evidence
that the hormone-occupied receptor undergoes rapid exchange
between interphase chromatin and the nucleoplasmic space. This
interaction of regulatory proteins with target sites in chromatin
was observed to be more dynamic process than previously
believed and lead to the proposal of “hit and run” mechanism of
receptor action.
During the mitotic stages, interphase chromatin undergoes
dynamic structural alterations that result in the formation of
highly condensed mitotic chromatin with compaction ratio up
to 1:10,000 [28]. This condensed packaging of eukaryotic
genome into chromatin is believed to play a role in the ab-
rogation of active gene transcription. In general, it has been
assumed that with the onset of mitosis, the active gene tran-scription by all the three RNA polymerases prevalent in in-
terphase nuclei of eukaryotic cells is silenced [29,30]. Studies
with simplified systems revealed that reversible phosphoryla-
tion of the basal transcription machinery and core histones by
cyclin-dependent kinases or its downstream kinases, chromatin
remodeling complexes and physical compaction of chroma-
tin repress transcription during mitosis by dislodging protein
complexes. [29–31]. In contrast to silencing, Sciortino et al.
[32] reported active transcription of cyclin B1 gene during
mitosis in HeLa cells. Majority of basal transcription factors,
RNA polymerases, enhancer-binding factors, histone acetyl
transferases (HATs) and deacetylases (HDACs) are disso-
ciated from the mitotic chromatin [29,30,33,34]. However,
emerging evidences are indicating that some of the major cel-
lular proteins, including ones having direct or indirect roles in
gene transcription function, remain associated with condensed
chromatin during mitosis. These include TATA binding pro-
teins (TBP), high mobility group protein (HMGB1, HMGB2,
HMGA1a), heat shock transcription factor 2 (HSF2), upstream
binding factor (UBF), RNA polymerase I, topoisomerase II,
insulator protein CTCF, co-activator PC4, transcription factors
Fox1 and Runx2 [35–44 and references therein]. During this
period of initial discoveries, we also reported the constitutive
association of a NR superfamily member to mitotic chromatin
throughout mitosis. The finding that a nuclear receptor, Preg-
nane and Xenobiotic Receptor (PXR), associates with con-
densed chromatin during all the stages of mitosis was novel and
hitherto unanticipated [45]. Nevertheless, with some other
proteins associating to mitotic chromatin, attempts have been
made to demonstrate that there is retention of gene expression
patterns by occupation of target gene promoters and that these
promoters are maintained in an open chromatin configuration
even during mitosis [32,41,43,44]. The issue, however, is still
an important challenge to resolve and needs to be pursued
further to establish the generality of the phenomenon more
concretely.
To examine the possibility if some other members of the NR
superfamily can also associate with the mitotic chromatin, we
initially examined two extensively studied members of this
group. Other than PXR reported previously, our choice was
restricted to other two important members i.e. AR and ERα
based on the fact that in unliganded state the former is a cyto-
plasmic protein while the latter is constitutively localized in the
nucleus. Clinically, both, AR and ERα are targeted with anti-
hormone drugs for treatments during hormone-responsive stages
of prostate and breast cancer respectively[1,11,46]. In the per-
spective of the dilemma that these cancerous cells transform
from hormone-responsive to hormone-independent stages, it is
speculated that prevention of transcription function of AR and
ERα by long-term exposure to anti-hormone drugs may actually
alter the epigenetic landscape of the targeted cells. This in turn
may impose upon these cells to undertake survival strategies and
proliferate via alternative survival routes [46,47]. Since AR and
ERα share major structural and functional similarities with each
other, present work though dealing primarily with AR, could
also provide important cues for endocrine therapy of ER-
responsive malignancies.
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2.1. Biochemicals
Prostate cancer drugs (antiandrogens including spironolactone, cyproterone
acetate, nilutamide), 5α-Dihydrotestosterone, nocodazole, Escort III & IV and
Cy3-conjugated anti-rabbit IgG raised in sheep, HRP-conjugated anti-rabbit
secondary antibodies raised in goat and Hoechst were procured from Sigma
Chemicals Co. (St. Louis, MO, USA). Casadox (bicalutamide) was a gift from
AstraZeneca (UK). All mammalian cell culture reagents were from Hyclone
(Logan, Utah, USA) and plastic-wares purchased from Corning Costar Corp.
(USA). Ni–NTA His–Bind matrix was a product from Qiagen (Valencia, USA).
Other general chemicals used were of analytical grade and were procured from
different commercial sources.
2.2. Plasmids
GFP-tagged human AR (GFP-AR) and wild type AR (pSG5-AR) were a gift
from Prof. O.A. Janne (University of Helsinki, Finland) and has been previously
reported [48]. GFP-hERα / GFP-SRC-3 and GFP-TBP were provided by Dr.
M. A. Mancini (Baylor College of Medicine, Houston, USA) and Dr. Sui Huang
(Northwestern University Medical School, Chicago) respectively. GFP-GRIP1
was obtained from Dr. B.M. Paschal (University of Virginia, USA) and is des-
cribed previously [23]. Human PXR was subcloned in frame between EcoRI and
BamHI restriction sites of pDsRed-Express-C1 (BD Biosciences, USA) from
GFP-PXR as previously described [45]. The full-length AR cDNAwas isolated
from GFP-AR and subcloned between BglII and BamHI restriction sites of
pDsRed-Express-C1 (BD Biosciences, USA) and is termed as RFP-AR. Full-
length TBP cDNAwas isolated fromGFP-TBP and sub-cloned betweenKpnI and
BamHI restriction sites of pDsRed-Express-C1 and is referred to as RFP-TBP.We
cloned full-length cDNA for AR intoEcoRI restriction site of pET-28a (Novagen)
and designated it as pET-AR that is having an N-terminal His-tag sequence.
2.3. Mammalian cell cultures and transient plasmid transfections
ATCC cell lines COS-1, HepG2, T47D and LNCaP were obtained from
National Cell repository (NCCS, India). COS-1 and HepG2 were grown in
DMEM supplemented with 10% FBS, 100 μg/ml penicillin and 100 μg/ml
streptomycin (complete medium), while LNCaP cells were grown in Nutrient
Mixture F-12 HAM, Kaighn's medium supplemented with 10% FBS, antibiotics
as above and 10−11 M DHT. T47D cells were grown in RPMI-1640 sup-
plemented with 10% FBS, antibiotics and 1 mM sodium pyruvate. The cultures
were maintained in a humidified incubator maintained at 5% CO2 and 95% air
atmosphere at 37 °C. Transient DNA transfections in COS-1 and HepG2 cells
were performed using Escort III and IV reagent respectively according to the
instruction provided by the manufacturer.
2.4. Prokaryotic expression and purification of full-length AR for
raising polyclonal antibodies
Expression and purification of full-length AR in E. coli BL21 cells was
performed as described earlier [49] with minor modifications. In brief, pET-AR
transformed E. coliBL21 (DE3) cells were grown up to 0.4 to 0.6 OD600 at 37 °C
and the AR expression was induced by 1 mM isopropyl-1-thio-D-galactopyrano-
side (IPTG) at 30 °C for 3 h. Over expressed protein from the inclusion bodies
fractionwas extractedwith urea extraction buffer [100mMsodium phosphate pH
8, 10 mM Tris–HCl, pH 8, 100 mM NaCl, 8 M Urea, 10 mM imidazol and 1×
protease inhibitors cocktail] at RT for 60 min. and subsequently loaded onto
0.5 ml of Ni–NTAHis–Bind matrix column. The matrix was washed three times
with washing buffer (100 mM sodium phosphate pH 8, 10 mM Tris–HCl, pH 8,
100 mM NaCl, 8 M Urea, 20 mM imidazol with protease inhibitors) and the
matrix-bound protein was eluted with elution buffer [100 mM sodium phosphate
pH 8, 10 mM Tris–HCl, pH 8, 100 mM NaCl, 8 M Urea, 250 mM imidazol and
protease inhibitors]. The eluted protein(s) recovered at different steps or as
fractions was analyzed for purification on SDS-PAGE. Immunization of New
Zealand white rabbit with 250 μg of purified AR protein recovered from the
preparatory SDS-PAGE gel was done as described elsewhere [49]. Rabbits usedfor raising AR antibody were cleared by institutional ethical committee and
housed in the central animal house, a core facility for Jawaharlal Nehru Uni-
versity, New Delhi, India.
2.5. Development of a stably transfected cell line constitutively
expressing human wild type AR
HepG2 cells were transfected with wild type AR expression plasmid and a
vector that contains neomycin resistance gene (pcDNA3.1) in a ratio of 10:1.
The cells were allowed to double once under non-selective conditions. Later,
cells were supplemented with the complete medium containing 400 μg/ml of
G418 (selective medium) and the medium was replaced every third day. After
two weeks of selection period, individual colonies were isolated and further
propagated under selective conditions. Individual clones were screened for the
stable expression of AR by indirect immunodetection and Western blotting
analysis using AR specific polyclonal antibodies.
2.6. Western blot analysis
HepG2, LNCaP, T47D and Hep-AR cells were cultured to a confluency of
∼80% in 60 mm culture dishes. Total protein was extracted from these cells using
trizole TRI reagent (Sigma) according to the instructions providedwith the reagent.
The proteins were finally dissolved in SDS-PAGE sample buffer, denatured by
heating at 95 °C for 5 min. and resolved on a 10% SDS-PAGE. Proteins were
electro-blotted onto the polyvinyldifluoridine (PVDF) membrane using semi-dry
transfer system (BioRad). After protein transfer, the blot was blockedwith 5% non-
fat dry milk in TBS for 2 h at room temperature and then incubated overnight with
AR antiserum at dilution of 1:5000 at 4 °C. The membrane was then washed three
times with TBST (TBS with 0.1% Tween-20) and incubated for 1 h with 1:10,000
dilution of horseradish peroxidase-conjugated anti-rabbit antibody. The bound
antibody complexes were detected using ECL method.
2.7. Mitotic Chromatin fractionation
COS-1 cells were transfected with GFP-AR and cultured in steroid-stripped
culture medium. After transfection, the cells were treated either with vehicle alone
or DHT (10−8 M) along with nocodazole (500 ng/ml) for 20 h. Mitotic chromatin
was isolated from cells after retrieving the nocodazole arrested cells by mitotic
shake-off as described [41]. Cells were collected by centrifugation at 500 ×g for
5 min at 4 °C, washed with cold PBS and resuspended in 75 mM KCl. After
20 min on ice, cells were pelleted at 500 ×g for 5 min at 4 °C and homogenized in
disruption buffer (10 mM Tris–HCl, pH 7.4, 120 mM KCl, 20 mM NaCl, 0.1%
Triton X-100, 2 mMCaCl2, 1× protease inhibitor cocktail and 0.1 mM PMSF) by
drawing through a 26-gauge needle 5–10 times. Cell lysates were pelleted by
centrifugation at 3300 ×g for 5 min at 4 °C and the supernatant was retained.
Pellets were washed once with disruption buffer and incubated again with
disruption buffer containing 0.4M NaCl. After incubation for 30 min, chromatin-
enriched fraction was collected by centrifugation at 40,000 ×g (Beckmann) for
15 min at 4 °C. Protein in the samples was estimated by CB-X™ Protein assay kit
(GenoTech).
2.8. Fluorescence microscopy and live cell imaging
COS-1 cells were seeded into 35 mm plates and allowed to grow to 70–80%
confluency. The following day, cells were transfected with 500 ng of GFP-AR,
GFP-ERα, GFP-PXR, RFP-AR, GFP-GRIP1, GFP-SRC-3, RFP-TBP or RFP-
PXR using Escort III transfection reagent. After 12–15 h of transfection
incubation, cells were supplemented with 5% steroid-stripped serum DMEM
followed by treatment with the respective ligands that included of 10−8 M 5α-
dihydrotestosterone (DHT), 10−8 M 17β-estradiol and 10− 6 M cyproterone
acetate, spironolactone, casadox, hydroxyflutamide, nilutamide or 20 μM of
rifampicin prepared in DMSO:ethanol (1:1) When required, cells were arrested
in mitosis by adding 0.1 μg/ml nocodazole to culture media for 12–16 h. After
treatment period, events for nuclear translocation, sub-nuclear compartmenta-
lization and mitosis were evaluated under the fluorescence microscope. With
DHT, cell treatment between 4–24 h produced same results; however,
antiandrogens being relatively slow acting were incubated with cells for 12–
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1 μg/ml) was added to the live cells at least 1 h prior to imaging. For the
statistical analysis of the association of steroid/nuclear receptors with mitotic
chromatin, the receptors expressing mitotic cells were counted in absence and
in presence of their respective ligands. At any time point 50–100 mitotic cells
were scored.
The fluorescent cells were viewed and imaged through a Nikon upright
fluorescence microscope (model 80i) equipped with water immersion objectives
and connected to cooled CCD digital camera (model Evolution VF, Media
Cybernetics, USA). Cell images were captured and analysed with Image ProPlus
version 5.0 software (Media Cybernetics, USA). The images were processed
using standard image processing techniques.
2.9. Procedure for cell fixation and permeabilization for
immunodetection in interphase and mitotic cells
Although a number of cell fixation and permeabilization procedures are
available that are in general use in immunocytology, some of these in several
instances have failed to detect the antigenic proteins associated with the
condensed mitotic chromatin [35,36,50]. To overcome the circumstantial
limitation when working with condensed chromatin, some of the cell fixation
and permeabilization procedures were carried out for systematic and
comparative analysis by immuno-probing the mitotic cells. Some of the cell
fixation procedures or their modification used includes (a) chilled methanol at
−20 °C, (b) 4% formaldehyde at RT, (c) 4% paraformaldehyde at RT, (d) chilled
ethanol at −20 °C with 5% and 10% (v/v) acetic acid and (e) chilled methanol atFig. 1. Association of GFP-tagged steroid/nuclear receptors with mitotic chromatin in
their subcellular localization in unliganded forms (i.e. AR = cytoplasmic; ERα and
receptors was expressed separately in COS-1 cells under steroid-free conditions as
control cells (unliganded) were treated with the vehicle alone or treated (liganded) wit
PXR with rifampicin 20 μM) as indicated in the figure. Ligand treatments were giv
Panel A shows the differences in chromosomal association of the three unliganded re
receptors with the mitotic chromatin. In the panels A and B, the left panels show the
DNA of the corresponding cells while the right panels show the merged images of the
without chromosomal association in presence or absence of the corresponding agon
values represent means±s.d. of three separate experiments. Scale bar, 5 μm.−20 °C with 5% and 10% (v/v) acetic acid. Irrespective of the procedures used,
after 20 min. of fixation, cells were rehydrated and permeabilized for 5 min. in
ice-cold PBS containing 0.1, 0.2 and 0.5% Triton X-100. Cells were then
incubated with blocking buffer (3% BSA in PBS) followed by incubations with
primary and secondary antibodies. Of all the procedures tested, the approach that
gave the most optimum immunodetection results with the mitotic cells (and also
interphase cells) is elaborated in the following protocols.
For indirect immunodetection, Hep-AR cell line and LNCaP cells were
cultured over sterile glass cover slips. After treatment with 10−8 M DHT for
24 h, The cells were washed thrice with 10 mM phosphate buffered saline (PBS)
and then fixed with chilled methanol (−20 °C) containing 5% (v/v) acetic acid
for 20 min. on ice. Following fixation, cells were incubated further for 5 min. in
ice-cold PBS containing 0.5% Triton X-100. The cells were then blocked in 3%
bovine serum albumin (BSA) in PBS for 1 h. For immunodetection, the cells
were incubated overnight with primary AR polyclonal antiserum at a dilution of
1:300 at 4 °C. After three washes with PBS, the cells were incubated with Cy3-
conjugated sheep anti-rabbit IgG (1:300 dilution) prepared in PBS with 3%
BSA. Hoechst-33342 was included with the secondary antibody preparation for
staining and visualization of the nucleus. The cells were rinsed three times in
PBS and the cover slips were mounted on a glass slide with 20% glycerol in PBS
and visualized under the fluorescence microscope.
2.10. Preparation of mitotic chromosome spreads for AR localization
To prepare mitotic chromosome spreads, Hep-AR stable cell line and LNCaP
cells were incubated in a medium containing10−8 M DHT and 0.1 μg/mlnocodazole arrested cells. A choice of three nuclear receptors was made based on
PXR = nuclear). For transient transfection, 500 ng of each of the GFP-tagged
described under “Materials and methods”. Following receptor expression, the
h their cognate agonists (AR with DHT 10−8 M, ERαwith 17β-estradiol 10−8 M,
en after arresting the cells in mitosis with 0.1 μg/ml nocodazole for 12–16 h.
ceptors while panel B shows a uniform agonist-mediated association of the three
GFP fluorescence for the receptors, the middle panels show the Hoechst stained
two fluorescence. Panel C shows a comparison (in percent of the cells), with or
ists. For the purpose of quantitation, 50–100 cells were scored per sample. The
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dislodged by swirling themedia. Themitotic cell enrichedmedia was centrifuged
and resuspended in hypotonic buffer (0.25% (w/v) sodium citrate, 37.5 mM
KCl). After incubation for 20 min. at 37 °C, cells were pelleted at 900 ×g for
10 min., re-suspended in 0.5 ml hypotonic buffer and 5 ml ME buffer (methanol/
glacial acetic acid in ratio of 4:1) was added and mixed gently. Cells were
repelleted and resuspended in fresh ME buffer. After 1 h incubation at room
temperature, cells were centrifuged as above and spread onto a coverslip and air-
dried. The cell spreads were then kept in blocking buffer and subjected to indirect
immunofluorescence with anti-AR antibody as described above.3. Results
3.1. Association of nuclear receptor superfamily members with
the mitotic chromatin: is it a general phenomenon?
Recently, while resolving the controversial issue of sub-
cellular localization of PXR we reported the first case of a
member of the NR superfamily that can associate with the
mitotic chromatin [45]. Whether liganded or not, PXR was
found to be a nuclear protein that constitutively associated with
the mitotic chromatin during all the stages of cell division. This
finding prompted us to undertake a systemic approach with
some other members of the superfamily. For this purpose, other
than PXR, we selected two well-characterized members of the
NR superfamily i.e. AR and ERα. It has been well established
that in unliganded state AR protein is localized in the cyto-
plasmic compartment while the ERα and PXR reside pre-
dominantly in the nuclear compartment [9 and references cited
therein]. For this purpose GFP-tagged receptors (AR, ERα,
PXR) were transiently expressed in COS-1 cells under ligand-
free culture conditions. For arresting the cells in mitosis no-
codazole was added to the culture media at the final con-
centration of 0.1 μg/ml. The sets of experimental cells were
treated at optimally known concentrations of their respective
ligands while the control cells were treated with vehicle alone
(DMSO:ethanol 1:1). AR expressing cells were treated with
10−8 M DHT, ERα expressing cells with 10−8 M of 17β-
estradiol while PXR expressing cells were incubated with
20 μM rifampicin. Following treatments, the cells were imaged
and scored under fluorescence microscope. Typical intracellular
profiles of receptor distribution during unliganded (Fig. 1A) and
liganded states (Fig. 1B) are shown with GFP fluorescence.
Corresponding cells showing chromosomal DNA stained with
Hoechst and merged images of the two fluorescence are also
shown. Fig. 1C shows the percent of mitotic cells revealing the
mitotic chromatin binding for unliganded and liganded recep-
tors. From the results it was evident that in liganded state all the
three receptors were capable of binding to the condensed mitotic
chromatin. However, this behavior in mitotic cells differed
when these receptors were in unliganded state. In case of GFP-
AR, the unliganded receptor did not associate with the mitotic
chromatin. On the contrary, unliganded GFP-ERαwas observed
to be associated only partially (in∼20% cells) while unliganded
GFP-PXR in all the mitotic cells was seen to be consistently
associated with the mitotic chromatin. Interestingly, unlike AR,
ERα has been reported to exist as a homodimer even in absence
of its ligand [51,52]. PXR on the contrary is reported to existas a homodimer or heterodimer with RXR under liganded as
well as unliganded states [53]. Whether dimerization of these
receptors in unliganded states could attain increased affinity to
chromatin without initiation of transcription is not clear. Also, at
the initial stages of these findings, it is difficult to assess if all
the cellular transcription factors encompass this behavior or it is
restricted to only some of the critical receptors executing un-
known but dedicated cellular functions.
3.2. DHT-activated AR binds mitotic chromatin during all the
stages of cell division
Transcription modulation by AR is a function that it imparts
in response to interaction with its physiological ligands. When
in ligand-bound state AR resides in the nuclear compartment
like all other members of the NR superfamily. However, in
unliganded state AR remains anchored to a number of cha-
perone proteins (Hsp70, Hsp90, immunophilins etc.) that help
in retaining the receptor primarily in the cytoplasmic compart-
ment [26]. For the purpose of studying the behavior of AR
during mitotic stages of normally proliferating cells, GFP-AR
was transiently expressed in COS-1 cells. As observed in no-
codazole arrested mitotic cells, in naturally dividing cells also,
the unliganded AR did not associate with the mitotic chromatin
while DHT-bound receptor showed a clear chromatin binding
during all the mitotic stages. Fig. 2 represents a typical profile of
unliganded and DHT-bound AR during interphase and in dif-
ferent stages of mitosis. When cultured in steroid-free condi-
tions these mitotic stages clearly demonstrated total absence of
AR association with the condensed mitotic chromatin (Fig. 2A).
As seen in Fig. 2B, DHT-bound AR was observed to be as-
sociated with mitotic chromatin during prophase, metaphase,
anaphase, telophase and cytokinesis. In interphase nucleus,
agonist-activated AR has been previously reported to redis-
tribute into fine structures that have been generally termed as
“nuclear foci” [18,19,23]. Interestingly these “nuclear foci”
appeared to co-migrate with the condensing chromatin and this
dynamic movement was observable up to prophase and me-
taphase of mitosis (Fig. 2B). However, after metaphase these
“nuclear foci” could not be resolved as separate entity probably
due to extreme condensation of chromatin. Observation made
above with live cell studies were further confirmed by bio-
chemical fractionation of mitotic chromatin from nocodazole
arrested COS-1 cells transiently expressing GFP-AR in pre-
sence or absence of DHT (Fig. 2C). The supernatant and the
chromatin fractions from DHT-treated cells were analysed by
western blotting using the AR polyclonal antibody described
herein. Results show that AR band is significantly more pro-
minent in chromatin of DHT-treated cells as compared to the
untreated control. In context to the studies conducted so far with
other relevant proteins, AR appears to be the first case of a
transcription factor whose association with the mitotic chroma-
tin can be modulated by its natural ligand. A few of the other
transcription factors (PXR, FOX1, zinc finger protein CTCF,
Runx2) showing association with the mitotic chromatin have
been reported during last couple of years [41,43–45]. However,
their association with the mitotic chromatin has been observed
Fig. 2. Agonist-mediated binding of GFP-AR to the mitotic chromatin throughout the mitotic stages. COS-1 cells were transiently transfected with 500 ng of GFP-AR
and incubated in steroid-free medium for 24 h. Following receptor expression the cells were treated with DMSO:ethanol (vehicle) for control cells or with 10−8 M of
5α-dihydrotestosterone (DHT). After incubation with DHT, GFP-AR that associated with mitotic chromosomes was recorded in live cells by fluorescence microscopy.
Hoechst was used as a fluorescent dye to visualize corresponding nuclei/condensed chromosomes. Panel A shows unliganded AR that does not associate with the
condensed chromosomes during mitosis. Panel B shows DHT-activated AR that binds to the condensed chromosome during all the stages of mitosis. In the
“unliganded GFP-AR” and “GFP-AR+DHT” set of images, the left panels show the GFP-tagged AR, the middle panels show the Hoechst stained DNA of the
corresponding cells while the right panel shows the merged images of the two fluorescence. The interphase cells and the mitotic stages of the naturally dividing cells
are indicated. Panel C: To confirm the above observation, biochemical fractionation of mitotic chromatin was performed in COS-1 cells transiently expressing GFP-
AR in unliganded and DHT-bound conditions as described in “Materials and methods”. The supernatant and chromatin-enriched fractions were analyzed by western
blot using the anti-AR polyclonal antibody. Western blot shows the supernatant and corresponding mitotic chromatin fractions (chromatin fraction) in absence and in
presence of DHT. As shown in figure GFP-AR is present in both the supernatant fractions in the absence and in the presence of DHT. While GFP-AR band is more
prominent in the mitotic chromatin fraction of DHT-treated cells. A faint band is detected in the chromatin fraction of untreated cells. These results further confirm that
GFP-AR binding to mitotic chromatin is DHT-dependent. Scale bar, 5 μm.
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3.3. A comprehensive analysis to overcome artifacts
introduced during mitotic cell fixation procedures
Association of PXR with mitotic chromatin was an un-
anticipated finding [45] and similar behavior of AR and ERα
during mitosis is somewhat intriguing. Though these studies
were conducted in living cells using GFP-tagged chimera, the
concern that GFP tagging to receptor can produce an un-
physiological receptor response needed to be experimentally
ascertained. In earlier instances, GFP-tagged TBP was found to
be associated with condensed mitotic chromatin but indirectimmunodetection of untagged TBP in fixed cells failed to show
existence of similar phenomenon [35]. Unavailability of an-
tigenic epitope(s) by the antibody used was also suggested as
a plausible reason for this failure. In this context, the limitations
of chemical fixatives and permeabilization reagents were also
highlighted by others when working with HMGB1 and HMGB2
(high mobility group box) proteins [36].
For confirming our observations more stringently with un-
tagged AR, we first purified full-length human AR and raised
polyclonal antibodies in rabbit against the whole protein. Ad-
vantages of using antibodies against full-length antigen were
perceived to be advantageous since such antibodies will access
multiple epitopes making immunodetection possible even if
some antigenic epitopes remain buried in the condensed
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another cell line stably transfected with wild type AR in HepG2
cells was prepared to authenticate our results obtained from
living cells. In this context, Fig. 3A shows results for AR
immunodetection in cell line expressing untagged wild type
receptor with the antibody raised against full-length receptor. In
our experiments, we could specifically detect the unliganded
AR in cytoplasm and DHT-bound receptor in the nucleus. The
antibodies generated were tested further by western blot ana-
lysis using whole cell extracts from low AR expressing T47D
cells and also in stably transfected HepG2 (Hep-AR) cells.
When compared to normal HepG2 cells (control) a band at theFig. 3. Preparation of polyclonal antibody against full-length AR and a cell line
stably expressing wild type AR. Prokaryotic expression of AR in E. coli BL21
and final purification with Ni–NTA His–Bind matrix was performed as
described under “Materials and methods”. Using AR antibody, stably transfected
Hep-AR cells were specifically examined for AR in hormone-free and hormone-
bound conditions (A). The unliganded AR was predominantly cytoplasmic
(−DHT) while the hormone-bound receptor was nuclear (+DHT) indicating the
specificity of the antibody. Panel B shows the western blot analysis for AR
constitutively expressed by HepG2 cells stably transfected with wild type AR
(Hep-AR) while the normal (untransfected) HepG2 cells do not show the
corresponding AR band. Human breast cancer cell line T47D revealed the
presence of endogenously expressed AR albeit at lower level. Molecular weight
markers by symbol M. Panel C shows the western blot analysis for the
expression level of endogenous AR by human prostate cancer cell line LNCaP in
interphase and mitosis in unliganded and liganded conditions. LNCaP cells are
arrested in mitosis by incubating with 500 ng/ml nocadozole for 20 h and treated
with 10−8 M DHTor 10−6 M of pure antiandrogen. Western blot analysis shows
that AR expression is more in interphase cell extracts as compared to mitotic cell
extracts seen in (interphase versus mitotic phase lanes). Also, DHT-bound AR
(+H) level is more in LNCaP cells while lower in unliganded (−H) or
antiandrogen-bound (+A) irrespective of cell cycle arrest. β-actin is served as a
protein loading control. Molecular weight markers are shown in lane M. Scale
bar, 20 μm.expected position of 110 kDa was clearly visible in both the cell
lines expressing AR (Fig. 3B). In LNCaP, a prostate cancer cell
line, we detected AR in varied conditions. In normally pro-
liferating cells DHT-bound AR was marginally at higher level
than in unliganded or antiandrogen bound state. Similarly, in
nocadozole arrested cells the AR relative levels also varied with
ligand status. However, it was clear that AR levels in interphase
cells were maintained at higher levels than in cells arrested in
mitosis (Fig. 3C). These results are in agreement with the
findings that agonist-bound receptor is more stable in cellular
milieu [54] and AR levels during mitosis are maintained at
reduced levels [55]. Once the experimental tools were opti-
mized we employed these in our forthcoming experiments.
In search for a suitable protocol for working with mitotic
chromatin we carried out a systematic and comparative analysis
of some of the prevalent procedures by probing DHT-activated
AR in LNCaP and Hep-AR cells transversing mitotic stages.
Amongst the various protocols described under “Methods”, the
one that gave the most optimum immunodetection results with
condensed chromatin was with chilled methanol with 5% acetic
acid (v/v) followed by permeabilization with 0.5%Triton X-100.
Chilled ethanol with 5% (v/v) acetic acid used by another group
in related studies with other transcription factor also gave com-
parable results [41]. Representative results from three major
fixation procedures evaluated in the present study are shown in
Fig. 4. AR immunodetection results obtained from mitotic cells
using two cell types expressing the mutant or wild type AR
divulged that cells fixed with chilled absolute methanol or
paraformaldehyde do not show significant AR bound to mitotic
chromatin. Majority of the immunodetected AR protein ap-
peared abrogated adjacent to mitotic chromatin with only some
cells showing a minor fraction of AR associated with condensed
chromatin. However, in our screening, cells fixed with chilled
methanol with 5% acetic acid (v/v), revealed a consistent as-
sociation of immunodetected AR with the condensed chro-
matin. The efficacy of the fixation methods was further tested by
fixing the COS-1 cells that expressed GFP-AR associated with
mitotic chromatin in presence of DHT. Using different cell fix-
ation methods, only methanol–acetic acid appeared superior in
retaining the receptor protein on mitotic chromatin (not shown).
Finally, with methanol–acetic acid cell fixation procedure,
mitotic stages of LNCaP and Hep-AR extending from prophase
to cytokinesis were produced and are represented in Fig. 5. It is
evident that untagged AR bound to DHT associates with mitotic
chromatin throughout mitosis as was observed with the GFP-
tagged receptor in live cell experiments.
3.4. Mitotic chromosomal spreads reveal a higher order
systematic distribution profile of AR on condensed chromatin
In a whole cell undergoing mitosis, the chromosomal details
cannot be resolved as explicitly as is possible with chromosomal
spreads. In a few related studies chromosomal spreads have
provided better details [37,41,42], and therefore, were taken
advantage of in the present study. In our experiments, chromo-
somal spreads were prepared from Hep-AR and LNCaP
cell lines after treatments with DHT. Following hormone
Fig. 4. Comparative analysis of cell fixation and permeabilization procedures for determining the optimum conditions in immunodetection of AR associated with
mitotic chromatin. AR expressing LNCaP and stable Hep-AR cell lines were used for the immunodetection of agonist-activated receptor during mitosis. LNCaP and
Hep-AR cells were cultured onto the glass cover slips, treated with 10−8 M DHTand allowed to incubate for 24 h. Subsequently, the cells were fixed with either chilled
methanol alone (first row) or 4% paraformaldehyde (second row) or with chilled methanol +5% acetic acid (third row). AR was immuno-stained with the anti-AR
primary antibody and a Cy3-conjugated secondary antibody (red), and DNAwas stained with Hoechst (blue). The merged images show the colocalization of AR with
mitotic chromatin. For each fixation procedure two representative cells are shown. Scale bar, 5 μm.
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immunodetection with anti-AR antibodies as described under
“Methods”. Results frommitotic chromosomal spreads prepared
similarly from the two cell lines are shown in Fig. 6. As
expected, AR was clearly associated with all the mitotic
chromatin. However, along the condensed chromatin the
receptor is visibly distributed unevenly. Spherical regions of
high receptor density can be easily distinguished from the areas
of little or no binding (Fig. 6 inset magnified). Similar results on
mitotic chromatin were also reported with transcription factor
CTCF [41]. Interestingly, in three-dimensional image analysis of
interphase nucleus, agonist-mediated “nuclear foci” formation
by AR has been roughly estimated to be between 250 and 400 in
number [17].Whether these spherical, receptor-enriched regions
on chromosomes are representatives of pre-existing “nuclear
foci” that were apparently engulfed during chromatin condensa-
tion, is a subject of speculation and warrants further
investigation.
3.5. Association of GFP-AR with mitotic chromatin is
discernible with the agonistic or antagonistic nature of ligand(s)
Over the last few years a number of laboratories have shown
that intranuclear homogenous distribution of steroid receptorsrapidly reorganize into punctate pattern (termed “nuclear foci”)
upon agonist binding [9,18,26]. From the studies in several
laboratories it is evident now that only agonist-bound receptor
having transcriptional competency could reorganize into “nu-
clear foci” representing potential sites engaged in gene tran-
scription. Pure antagonist, though efficiently bind and translocate
the cytoplasmic receptor into nuclear compartment, revealed
only homogeneous intra-nuclear pattern. Additionally, since
mixed agonist–antagonists have some innate agonist property,
they also provided similar punctate pattern. This correlated well
with transcriptional status of the receptor and was considered
indicative of an important regulatory process by numerous other
reports. Recent studies with GFP-AR using FRAP revealed
significant differences in AR mobility in interphase nucleus/
chromatin depending on the nature of ligand i.e. agonists or
antagonists. Unliganded or antagonist-bound AR was observed
to be significantly more mobile as compared to agonist-bound
AR. It is postulated that antagonist-bound AR has extremely
short residency on chromatin that is not enough to support
transcriptional activation [6,20].
Keeping in view the above background, we selected DHT as
the most preferred AR agonist along with some other well-
studied antiandrogens that are used in treatment of androgen-
dependent prostate cancer. These antiandrogenic drugs have
Fig. 5. Association of untagged agonist-activated AR with the mitotic chromatin performed under optimal cell fixation and permeabilization procedure. Indirect
immunofluorescence experiments were carried out on LNCaP and Hep-AR stable cells fixed with chilled methanol +5% acetic acid. Following immunodetection,
different mitotic stages that included prophase, metaphase, anaphase, telophase and cytokinesis in normally dividing cell were imaged and presented above. AR was
stained with the primary anti-AR antibody and a Cy3-conjugated secondary antibody (red), and DNAwas stained with Hoechst (blue). The merged images show the
colocalization of AR and mitotic chromatin. Scale bar, 5 μm.
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cytoplasmic AR to the nuclear compartment. Of these, three
drugs i.e. casodex, hydroxyflutamide and nilutamide are pure
antagonist whereas cyproterone acetate and spironolactone
are of mixed agonist–antagonist nature. Whether dynamicFig. 6. Distribution of immunodetected AR on mitotic chromosome spreads. Mitotic
LNCaP and stably transfected Hep-AR cell line. Indirect immunofluorescence was c
(Red, left panel). DNAwas stained with Hoechst (Blue, middle panel). The merged
merged image from Hep-AR cell line expressing wild type AR is highlighted and in
multiple areas with intense focal distribution of AR on mitotic chromatin. These high
5 μm.association of AR with mitotic chromatin will also distinguish
between agonist and antagonist property of these ligands was
revisited in live cell experiments using GFP-AR. In this attempt,
other than DHT, we tested all the above-mentioned therapeutic
antiandrogens. As expected, the two mixed agonist–antagonistchromosome spreads were prepared with DHT-activated prostate cancer cell line
arried out with the anti-AR antibody and a Cy3-conjugated secondary antibody
images show the colocalization of AR and DNA (right panel). A portion of the
dicated with an arrow. The magnified merged image on extreme right exhibits
er order structures were visible in both the cell lines represented here. Scale bar,
Fig. 7. GFP-AR activated by pure or partial agonists reveal formation of “nuclear foci” during interphase and chromosomal docking during mitosis. GFP-AR was expressed in COS-1 cells and challenged with different
ligands including drugs used in prostate cancer treatment. In interphase cells, unliganded GFP-AR remains partitioned in the cytoplasmic compartment (A row 1). Upon treatment with pure agonist (DHT) or mixed
agonist–antagonist (CA, spironolactone) GFP-AR enters nucleus and forms “nuclear foci” (A, row 2 to 4) and also associates with mitotic chromatin (B, row 2 to 4). However, with pure antagonists (casodex, nilutamide,
hydroxyflutamide), the receptor is homogeneously distributed, marked by absence of “nuclear foci” in the nucleoplasm (A, row 5 to 7), and, does not associate with chromatin during mitosis (B, row 5 to 7). The results
from GFP-AR shown in panels A and B were confirmed by immunocytology in a cell line stably expressing untagged wild type AR and are shown similarly arraged in panels C and D. The results from GFP-tagged AR
were in agreement with immunodetected wild type AR. In panels A to D, the left panels show AR, the middle panels show the nuclear/chromatin staining with Hoechst and the right panels exhibit the merged images of
the corresponding fluorescent cells. CA = cyproterone acetate. Scale bar, 5 μm.
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Fig. 8. Agonist-activated AR associates with mitotic chromatin but does not
recruit coactivator GRIP1. COS-1 cells were co-transfected with RFP-AR and
GFP-GRIP1 and cultured in steroid-free culture medium for receptor expression.
In the interphase nuclei, unliganded RFP-AR is visible as a predominantly
cytoplasmic protein while GFP-GRIP1 is seen as nuclear protein (untreated
interphase row). During mitosis, both the unliganded RFP-AR as well as GFP-
GRIP1 do not associate with the mitotic chromatin (untreated metaphase row).
Upon treatment with DHT, RFP-AR enters nucleus and forms nuclear foci and
colocalizes with GFP-GRIP1 in interphase cells (DHT-treated interphase row).
However, in mitotic cells, agonist-activated AR associates with mitotic chro-
matin but fails to recruit GFP-GRIP1 (DHT treated metaphase row). From left,
panel 1 shows the RFP fluorescence for AR while panel two shows the GFP
fluorescence for GRIP1. Panel 3 illustrates the merged images from the two
fluorescence in panel 1 and 2. Panel 4 exhibits the Hoechst stained nuclei/mitotic
chromatin of the corresponding cells.
Fig. 9. Agonist-mediated binding of AR onto the mitotic chromatin of living
cells is neither impeded nor prevented by coexpressed TBP or PXR. COS-1 cells
were co-transfected with GFP-AR and RFP-TBP (A) or RFP-PXR (B) and
cultured in steroid-free culture medium for receptor expression. In the interphase
cells, unliganded GFP-AR is visible as a predominantly cytoplasmic protein
while RFP-TBP and RFP-PXR are seen as nuclear proteins. In mitotic meta-
phase, unliganded GFP-AR did not associate while RFP-TBP and RFP-PXR
constitutively associated with the mitotic chromatin. Though the mitotic
chromatin are preoccupied with RFP-TBP or RFP-PXR, DHT-activated GFP-
AR efficiently occupied the binding sites on the mitotic chromatin implying that
the association with chromatin is apparently non-competitive in nature. Scale
bar, 5 μm.
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into “nuclear foci” while the pure antagonists (casodex,
nilutamide, hydroxyflutamide) showed homogeneous AR
distribution in the interphase nucleoplasm (Fig. 7A). Interest-
ingly, AR showed binding to mitotic chromatin only with the
drugs (cyproterone acetate, spironolactone) that exhibited
induction of “nuclear foci” (Fig. 7B). On the contrary,
association of AR with the mitotic chromatin was abrogated
when bound to pure antagonists. The above results obtained
from GFP-tagged AR, transiently expressed in COS-1, were
authenticated in a cell line (Hep-AR) that stably expresses
untagged wild type AR analogous to endogenous levels in
LNCaP expressing the mutant AR. The effect of different
ligands on AR binding to chromatin, obtained from live cells
studies were in agreement with the results observed with cell
line expressing wild type AR (Fig. 7C and D). These results
conclusively established that of the five therapeutic drugs only
those having pure or partial agonistic properties could inflict
chromosomal binding of the receptor.
3.6. GRIP1 that colocalizes with AR during interphase is
aborted from mitotic chromatin during cell division
Recent studies have convincingly shown that some of the
critical co-activators of nuclear receptors are recruited into the
“nuclear foci” of the interphase cells. Formation of these foci isagonist-dependent and could be correlated with the transcrip-
tionally active state of the receptor [9,18]. With respect to AR
and ER, studies primarily based on live cell imaging, have
already indicated that nuclear receptor co-activators like GRIP1,
TIF2, SRC1, SRC3 and etc. co-localize in “nuclear foci” with
the agonist-activated but not with pure antagonist-bound re-
ceptor [21–25]. Essentially, pure antagonist-bound nuclear
receptors have never been reported to form “nuclear foci” but
were observed to display a homogeneous nucleoplasmic recep-
tor distribution. Therefore, in this context, it was interesting to
explore whether co-activators are colocalized with AR on con-
densed chromatin in mitotic cells. Results obtained from this
query are presented in Fig. 8. COS-1 cells were co-transfected
with RFP-AR and the co-activator GFP-GRIP1 and cultured for
protein expression in steroid-free media. After expression
period, the relevant set of cells were treated with DHT
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evident that under steroid-free culture condition RFP-AR was
expressed as a cytoplasmic protein while GFP-GRIP1 resided
predominantly in the nuclear compartment of the interphase
cell. Under similar culture conditions in the mitotic phase none
of the two proteins associated with the mitotic chromatin.
However, in DHT-activated state, both, RFP-AR and GFP-
GRIP1 were observed to be predominantly residing in the
nucleus. In agreement with the previous reports, the merged
images of the red and green fluorescence showed appearance of
significant level of yellow fluorescence at the “nuclear foci”
which is indicative of co-localization of two proteins. However,
results observed from DHT-activated mitotic chromatin
revealed that the two proteins that were reported to co-localize
in “nuclear foci” of interphase cells reveal dissimilar behavior.
While the DHT-activated AR associated with the mitotic
chromatin, the co-activator GRIP1 was not recruited along
with the AR. This implies that the formation of transcriptionally
competent complex is an event specific to interphase nucleus
and not to mitotic chromatin. Recently, another co-activator
SRC-3 has been similarly observed to be co-localized with ER
in interphase cells [25]. In our preliminary study, GFP-SRC-3
also did not exhibit any association with the mitotic chromo-
somes (not shown).
3.7. Mitotic chromatin pre-occupied by other over-expressed
transcription factors does not prevent subsequent binding of
agonist-activated AR
TBP and PXR are among the first few proteins that are
reported to bind to mitotic chromatin and are also involved in
gene transcription. The finding that DHT-activated AR also
associates with the mitotic chromatin raised the pertinent ques-
tion if the chromatin sites for receptor docking are specific or
general in nature for each transcription factor. Since docking of
AR could be modulated by DHT, it was possible to preoccupy
the chromosomal docking sites constitutively by another tran-
scription factor and then attempt to load the AR by DHT acti-
vation. If the docking sites are general in nature and stay pre-
saturated by another transcription factor, DHT-activated ARwill
be subsequently prevented from chromosomal binding. Fig. 9
shows results from live cell imaging where either RFP-tagged
TBP (RFP-TBP) or RFP-tagged PXR (RFP-PXR) is co-
expressed along with GFP-tagged AR. Fluorescent distribution
in interphase cells shows that TBP and PXR are nuclear proteins
while unliganded AR is compartmentalized in the cytoplasm.
Results from mitotic cells, co-expressing RFP-TBP and GFP-
AR in steroid-free culture conditions, showed that TBP remains
constitutively associated with the mitotic chromatin while AR
remains unbound. Addition of DHT to culture media induced
efficient AR binding to the mitotic chromatin without any ap-
parent hindrance (Fig. 9A). We further conducted similar ex-
periment by co-expressing RFP-PXR and GFP-AR since former
is also a member of the NR superfamily (Fig. 9B). Similar to the
results obtained with TBP, PXR that pre-occupied the mitotic
chromatin did not inhibit or impede the DHT-activated AR
docking onto the mitotic chromatin. These results suggested thatthe chromosomal docking sites are distinct or specific for these
transcription factors and cannot be competed out by each other.
4. Discussion
During the last few years, several key components of gene
transcriptional machinery including transcription factors that lie
within or outside the NR superfamily have been reported to
undertake a dynamic association with the mitotic chromatin
[41,43–45]. This dynamic docking of transcription factors onto
the condensed mitotic chromatin should have important phys-
iological significance. In this report, we have documented ana-
lysis of a hitherto unreported dynamic behavior of AR, an
extensively studied member of this superfamily. A significant
amount of recent data showing association of proteins to mitotic
chromatin in living cells has been generated using expression of
GFP-tagged chimeric proteins. Notably, in these experiments
there have been instances when the observations made in live
cells could not be reproduced in fixed cells used for indirect
immunodetection [35,36]. In agreement with Pallier et al. [36],
we also observed that use of chemical fixatives could be a
determining factor in success or failure of immunodetection
results obtained with mitotic chromatin. These variations can
also be protein specific since in our experience PXR association
with mitotic chromatin was obtainable with most of the cell
fixation procedures while AR gave optimal results with chilled
methanol plus 5% acetic acid. These differences may be attri-
buted, at least in part, to the affinity with which the observed
protein binds to the mitotic chromatin. Nonetheless, this is a fine
example of experimental artifacts that may be introduced by
some of the cell fixation procedures and also justifies the ge-
neral superiority of live cell studies over the fixed cells. Ad-
ditionally, the limitations of the cell fixation procedures appear
to have contributed in delaying the observation of this sig-
nificant phenomenon. Notably, in normal cell culture conditions
mitotic cells are not present in large numbers and the adherent
mammalian cells undergoing mitotic division will generally
become round with nuclear structure apparently visible as dis-
integrated. Such cells, therefore, can be easily confused with the
apoptotic cells, thereby, escaping attention of the observer
during protein localization.
Employing GFP-tagged AR and ERα we observed agonist-
mediated docking of these receptors onto the mitotic chromatin
during cell division. In our extended studies using GFP-AR, we
have shown a distinctly differential response to androgenic and
pure anti-androgenic therapeutic drugs used in targeting AR.
When bound to drugs with intrinsically absolute or partial ag-
onistic properties, AR associated with the mitotic chromatin.
Conversely, the pure antagonists that are previously reported to
bind and subsequently translocate unliganded AR from cyto-
plasm to nuclear compartment do not provoke such association
with the mitotic chromatin. Conceivably, with similar drugs, a
correlation to AR dynamic response analogous to formation of
“nuclear foci” in interphase nuclei is also evident on mitotic
chromatin. Only those drugs that generated “nuclear foci” were
potent in imparting docking of AR onto mitotic chromatin while
others that do not induce “nuclear foci” abrogated receptor
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further substantiated by immunocytology of untagged wild type
AR in a cell line stably expressing the receptor near endogenous
levels.
Previous studies of GFP-AR, using FRAP analysis, revealed
significant differences in dynamics of AR-chromatin association
with unliganded/antagonist-bound AR when compared with
agonist bound AR [6]. The rate of dissociation of pure anta-
gonists (casodex, hydroxyflutamide) bound AR from chromatin
was significantly higher than agonist (DHT) and partial agonists
(cyperoterone acetate) bound AR [6,20]. These results support
our observation of ligand-dependent differential behaviour of
AR onmitotic chromatin. The agonist/partial agonists boundAR
associates more stably with interphase chromatin. On the con-
trary, in the presence of antagonists the resident time of AR on
chromatin is much less as compared to agonist. Whether similar
ligand-dependent phenomena are also occurring on the mitotic
chromatin platform needs to be established concretely. Alter-
natively, ligand-dependent N/C-termini interactions of AR may
be involved in inflicting differences in mitotic chromatin bind-
ing. In this context, N/C-terminal interactions have already been
reported to stabilize receptor association with interphase chro-
matin [5,6]. It is believed that only AR agonists lead to N/C
interactions whereas AR antagonists prevent these intramole-
cular interactions [4]. Future studies are expected to unravel
the AR dynamics/mobility on mitotic chromatin and also ex-
plain how agonistic–antagonistic nature of different ligands al-
ters receptor relationship with mitotic chromatin.
A remarkable difference in behavior of agonist-activated AR
was with recruitment of co-activators. Recruitment of ligand-
activated transcription factors and co-activators in the “nuclear
foci” of interphase cells have been documented in significant
details [21–25]. Contrary to observations in interphase nuclei
we found that AR though associates with the mitotic chromatin
in agonist-dependent manner, the co-activator(s) stay aborted.
This is suggestive of a transition in behavior of agonist-bound
transcription factor from being transcriptionally active (during
interphase) to transcriptionally inactive or silenced (during mi-
tosis). In this perspective, amongst the previously reported
proteins, AR is first example of a transcription factor whose
association on mitotic chromatin platform can be modulated in a
ligand-specific manner. If found to be a general phenomenon,
this dynamic property of steroid/nuclear receptors by therapeu-
tic ligands may provide a composite screening protocol to some
of the emerging technologies that are being forwarded for
analyzing newer drugs and ligands [50,56,57]. Also, it will be
interesting to determine if these properties could be exploited to
establish the nature of molecular interventions that confers most
desirable therapeutic benefits.
We have shown that agonist-mediated binding of AR onto
the mitotic chromatin of living cells is neither competed nor
prevented by co-expression of other mitotic chromatin binding
proteins. These results suggested that the chromosomal dock-
ing sites are distinct or specific for these transcription factors
and cannot be competed out by each other. If these factors
were bound to the non-specific sites, an increase in cellular
abundance of other non-site-specific competitor would affectthe chromatin binding of AR. Such competitive interaction
between the non-site-specific chromatin binding factors are
well described in case of global non-specific binding factor H1
where its interaction on chromatin is modulated by a network
of other non-site specific competitors such as HMGs which
lead to reduction in the association of H1 with chromatin [58].
However, in our case results obtained with TBP and PXR that
pre-occupied the mitotic chromatin did not influence the
ligand-mediated docking of AR onto mitotic chromatin. This
study has important significance since specificity and non-
specificity of interaction on mitotic chromatin could be a
relevant query. In this context, our observations suggest that
these factors associate on distinct binding sites on to the mitotic
chromatin.
The present study has significant relevance in the perspective
of the recently emerging concepts of “epigenetic marking” and
“gene book-marking” [59,60]. “Epigenetic regulatory processes”
govern chromatin structure through covalent modification of
histone substrates via methylation, acetylation, phosphorylation
or ubiquitination processes [61,62]. In simple analogy to these
epigenetic regulatory processes, “gene book-marking” by ligand-
activated transcription factors can be broadly defined as a mech-
anism used in transmitting the pattern of active gene transcription
from interphase nucleus, via mitosis, to the emerging daughter
cells, thereby, ensuring inheritance of progenitor's active gene
transcripts to the progeny [45,60,63]. The cyclic process of
transmitting the pre-existing transcription status from the un-
condensed chromatin of interphase cell to condensed chromatin
duringmitosis and then final re-emergence of active transcription
machinery during return to de-condensation state may be a
natural process. With respect to ligand-modulated transcription
factors this feed-forward transmission, by receptors themselves,
over the generations, may also encounter active gene pattern
modifications depending on appearance and disappearance of
physiological ligands. However, in view of the “hit and run”
mechanism of action of steroid/nuclear receptors, it remains to be
investigated if the nature of ligand-activated transcription factors
with mitotic chromatin is as dynamic as during interphase or is
relatively static [6,27].
In some of the human malignancies (like prostate or breast
cancer) the involvement of some of the members of ligand-
modulated transcription factors (primarily AR and ERα) is
physiologically and clinically important. Aberrant behavior or
dysfunction of receptor signaling is known to lead to some of
these human ailments. Testimony towards importance of these
receptors as therapeutic targets is evident by the fact that a large
number of commonly prescribed drugs act via nuclear receptors.
However, in prostate and breast cancers treatments with anti-
hormone ligands have provided only interim relief, but sub-
sequently, lead to re-emergence of advanced stages of disease
progression when these drugs become ineffective. It is en-
visaged that silencing of transcription function of targeted
transcription factors by anti-hormone drugs over long period
may alter the natural gene book-marking profile, thereby, in-
flicting upon cells to undertake alternative cell survival and
proliferation strategies. Hence, during anti-hormone therapy,
active gene transcripts offered to progeny from its progenitor for
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which may lead to either cell elimination or survival as ad-
vanced progression of a malignancy. Though speculative, it is
possible that in absence of such molecular intervention, for
example, normal transmission of inheritable active gene tran-
scripts carried during mitosis help a “prostate or breast cell” to
emerge as “prostate or breast cell” rather than a new genre.
In conclusion, we highlight an example of agonist-mediated
docking of amember of the ligand-activated transcription factors
onto the mitotic chromatin, in both, living and fixed cells. Since
the association of AR onto the mitotic chromatin platform obeys
the intrinsic mode of action of natural and clinical ligands,
therefore, it may offer a novel paradigm for understanding the
concerted action of ligand–receptor interactions in perspective
of normal physiology and clinical background.
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